HILLENBRAND INDUSTRIES INC

Similar documents
FORM8-K HILLENBRAND,INC.

WALGREEN CO. FORM 8-K (Unscheduled Material Events) Filed 6/5/2006 For Period Ending 6/5/2006

DCP MIDSTREAM, LP FORM 8-K. (Current report filing) Filed 04/13/12 for the Period Ending 04/09/12

FORM8-K HILLENBRAND,INC.

VICAL INC FORM 8-K. (Current report filing) Filed 11/02/06 for the Period Ending 11/02/06

PIERIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter)

RULES OF CONDUCT OF INSIDERS RESPECTING

INVESTOR PRESENTATION

WALGREENS BOOTS ALLIANCE, INC.

Inovio Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)

ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs

Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical

AstraZeneca to acquire MedImmune for $58 per share in a fully recommended, all-cash transaction with a total enterprise value of $15.

Evofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update

DARA Reports Year-End 2012 Financial Results

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS

January 30, 2018 Dow Wilson President and Chief Executive Officer

Investor Presentation

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE

Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

Shareholder Presentation Annual Meeting 2018

Argos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results

Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia. -Broadens Roche Nicotinic Alpha-7 Alliance-

VolitionRx Announces First Quarter 2016 Financial Results and Business Update

Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) (801)

Investment in MGC Pharmaceuticals

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014

XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes

HALOZYME REPORTS SECOND QUARTER 2018 RESULTS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K

Dainippon Pharmaceutical and Sumitomo Pharmaceuticals Finalize Merger Agreement

Capital Senior Living Corporation

ABSOLUTE NNN LEASE 19 Years Remaining 8815 Stagecoach Rd. Little Rock, AR 72210

ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update

For personal use only

For personal use only

- Plans Commercial Launch of three dosing options for Excellagen in pre-filled syringes

Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company)

Clovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET

Hillenbrand Industries

ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update

Forward-Looking Statements

www. isotopeworld.com Advanced Medical Isotope Corporation

34 th Annual J.P. Morgan Healthcare Conference

FIRSTQUARTER2018 RESULTSPRESENTATION

ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update

New Markets Tax Credit CDE Certification Question & Answer

Slide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO

Developing & Commercializing Targeted Small Molecule Drugs in Cancer

Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019

Infinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results

Small-Cap Research. Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final Guidance for Phase 3 Protocol for TSC in Inoperable GBM OUTLOOK

FEDERAL NATIONAL MORTGAGE ASSOCIATION FANNIE MAE

Avenue Therapeutics, Inc. August 2016

Emisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington D.C

Avenue Therapeutics, Inc. May 2017

ASX Announcement 22 June 2017

The power of innovation to save lives

22nd Century Group, Inc. (XXII - $ Buy) Q1 Far Ahead of Expectations

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K

TSX Venture: RVV OTCQB: RVVTF

Investor Presentation June 2012 NASDAQ: CEMI

DelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75)

VistaGen Therapeutics, Inc. (Exact name of registrant as specified in its charter)

Letter to Shareholders SEMI-ANNUAL REPORT 2008

Eiger BioPharmaceuticals Reports Third Quarter 2016 Financial Results

Wednesday 26 th November 2008 The ASX Company Announcements office: Chairman s AGM Address

Avenue Therapeutics, Inc. September 2016

QUESTIONNAIRE ANTI MONEY LAUNDERING (Including Counter Terrorist Financing, Financial Sanctions Monitoring, KYC)

AVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET

BVI Limited Partnership Hedge Funds: Calling Japan

Delivering Results POSITIONED FOR GROWTH. Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental

Endesa 1Q 2017 Results 09/05/2017

MYOS RENS Technology CEO Joseph Mannello Issues Letter to Shareholders

Investor Presentation

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018

Report to the GAVI Alliance Board 7-8 July 2011

36th Annual J.P. Morgan Healthcare Conference. Kevin Conroy, Chairman and CEO January 9, 2018

Annex 1. CHOONG YEE HOW List of past directorships. 1. Hong Leong Islamic Bank Berhad. 2. Promilia Berhad. 3. HL Asset Management Pte Ltd

THE COMMUNITY FOUNDATION OF SINGAPORE. Annual Report for the Year Ended 31 March 2012

LEERINK GLOBAL HEALTHCARE CONFERENCE. Marino Garcia EVP, Chief Strategy Officer February 15, 2017

HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)

Introductory Presentation

Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference

Synergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation

THE COMPLEXITIES OF M&A IN THE CANNABIS INDUSTRY. Presented by Robert T. Hoban, Esq.

Report for the fourth quarter of 2016 and subsequent events (Un-audited)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT

Interim report Second quarter 2017 and subsequent events (Unaudited)

Tamsulosin Hydrochloride 0.4 mg Capsule

Why More Chinese Businesses Are Choosing the BVI for Offshore Investment: A Move To Quality

PRICE DEMERS & CO. Barristers, Solicitors & Notaries Public

Jeff Balser, M.D., Ph.D., President and CEO of Vanderbilt University Medical Center, and Dean, Vanderbilt University School of Medicine.

AstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance. Becoming Global Leaders In Diabetes

The Dental Corporation Opportunity

Transcription:

HILLENBRAND INDUSTRIES INC FORM 8-K (Unscheduled Material Events) Filed 2/17/2004 For Period Ending 2/13/2004 Address 700 STATE ROUTE 46 E BATESVILLE, Indiana 47006-8835 Telephone 812-934-7000 CIK 0000047518 Industry Scientific & Technical Instr. Sector Technology Fiscal Year 09/30

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2004 HILLENBRAND INDUSTRIES, INC. (Exact name of registrant as specified in its charter) Indiana 1-6651 35-1160484 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 700 State Route 46 East Batesville, Indiana 47006-8835 (Address of principal executive offices) (Zip Code) Registrant s telephone number, including area code: (812) 934-7000 Not Applicable (Former name or former address, if changed since last report.)

Item 5. OTHER EVENTS. On February 13, 2004, the Company announced that it had reached a definitive agreement for the sale of its wholly-owned subsidiary, Forethought Financial Services, Inc. and its subsidiaries ( Forethought ), a specialty insurance holding company serving the pre-need financial services market, to FFS Holdings, Inc., an acquisition vehicle formed by The Devlin Group, LLC. Total nominal consideration for the transaction is expected to approximate $280 million, including certain Forethought assets retained by Hillenbrand. This announcement is more fully described in the press release filed as Exhibit 99 to this Current Report of Form 8-K. The contents of such Exhibit are incorporated herein by reference. Item 7. FINANCIAL STATEMENTS AND EXHIBITS. (c) Exhibit. 99 Press release dated February 13, 2004 issued by the Company. 2

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HILLENBRAND INDUSTRIES, INC. DATE: February 17, 2004 BY: /S/ Scott K. Sorensen 3 Scott K. Sorensen Vice President and Chief Financial Officer DATE: February 17, 2004 BY: /S/ Gregory N. Miller Gregory N. Miller Vice President Controller and Chief Accounting Officer

EXHIBIT INDEX Exhibit Number Exhibit Description 99 Press release dated February 13, 2004 issued by the Company. 4

Exhibit 99 HILLENBRAND INDUSTRIES Press Release HILLENBRAND INDUSTRIES ANNOUNCES AGREEMENT TO SELL FORETHOUGHT FINANCIAL SERVICES, INC. FOR TOTAL NOMINAL CONSIDERATION OF APPROXIMATELY $280 MILLION Buyer is FFS Holdings, Inc., an entity organized by a group of financial services executives, led by Robert Devlin, former chairman, president and CEO of American General Corporation BATESVILLE, IND., FEBRUARY 13, 2004 Hillenbrand Industries, Inc. (NYSE:HB), a leader in the health care and funeral services industries, announced today that it has reached a definitive agreement for the sale of its wholly-owned subsidiary, Forethought Financial Services, Inc. and its subsidiaries ( Forethought ), a specialty insurance holding company serving the pre-need financial services market, to FFS Holdings, Inc., an acquisition vehicle formed by The Devlin Group, LLC. Total nominal consideration for the transaction is expected to approximate $280 million, including certain Forethought assets retained by Hillenbrand. This excludes a dividend received by Hillenbrand in December 2003 from Forethought in the amount of approximately $29 million made in anticipation of the transaction. Last year, Forethought contributed approximately $347 million, or 17 percent, of Hillenbrand s $2.0 billion in total revenues. Frederick W. Rockwood, President and Chief Executive Officer of Hillenbrand Industries, said, Forethought over the years has delivered profitable growth. It has been, and remains, a great company comprised of great people. Despite that, there are several reasons we ve announced the transaction at this time. First, managing a large insurance and financial services company is very different than managing companies that manufacture products and provide related services. Second, a financial services company is subject to a variety of outside influences, including exposure to financial market volatility and there have been times in the past that financial market volatility has masked Hillenbrand s operating results. Third, Forethought s strategic priorities and opportunities are inconsistent with those of Hillenbrand s thus separating Forethought from our other operating companies should allow management to better focus on achieving our strategic goals. It is for these reasons that our management, Board of Directors and outside advisors launched a comprehensive review of strategic alternatives and concluded that the best interests of our shareholders, customers and employees would be served by the sale of Forethought allowing us to focus our resources on future growth opportunities in the health care marketplace, and maintain our longstanding commitment to Batesville Casket Company. Under the terms of the transaction, FFS Holdings, Inc., will acquire all of the common stock of Forethought and its subsidiaries for a combination of cash, seller financing, certain retained assets of Forethought and stock warrants. Hillenbrand will receive additional estimated cash proceeds in the transaction of between $48 and $53 million, provide seller financing in various forms with an estimated face value of $136 million, retain certain partnership assets of Forethought with an estimated value of between $90 and $95 million and receive warrants to acquire up to 5 percent of the common stock of FFS Holdings, Inc. This results in total nominal consideration of approximately $280 million, subject to adjustments. The seller financing will be subject to an estimated discount of between $30 and $35 million to reflect a market rate of return on the financing, which is expected to be recognized in future periods as accretion on the underlying financial instruments. The transaction will result in a loss, which will also generate significant tax benefits. However, as a result of limitations on Hillenbrand s ability to utilize the resulting capital losses, tax benefits recognized in conjunction with the sale will initially be limited to ordinary losses. We expect to recognize a net loss on 1

the divestiture of between $90 and $100 million, plus transaction fees and subject to adjustment for changes in the business between now and closing. Stephen R. Lang, President and Chief Executive Officer of Forethought, said, This is great news for our customers and employees. Under the umbrella of FFS Holdings, Inc., whose principals have significant expertise in financial services, we will have opportunities to further enhance the range and depth of our products and services to our customers and reach our full business potential. We will remain in Batesville and our focus will continue to be pre-need funeral planning products and services. We are excited by the prospect of working with the principals of FFS Holdings. Bob Devlin, Rod Hawes, Jr., Bill Berkley, Mike Poulos and Doug Schair represent some of the most experienced and successful insurance executives in the industry and we believe under their stewardship, Forethought will be able to continue to grow and provide its customers and consumers with excellent value. These individuals have worked with each other in various capacities for over 35 years. Mr. Rockwood added. Our decision to exit the financial services business does not diminish our 100 year-old commitment to funeral service. We are as focused as ever on providing innovative, high-value caskets and cremation products to funeral directors and their client families. Throughout the sale process of Forethought, it is important that customers of Forethought and Batesville Casket understand that we will honor each and every Forethought policy and all of our Total Casket Protection Program commitments. The investment banking firm of Keefe Bruyette & Woods, Inc. (KBW) and the law firm of LeBoeuf, Lamb, Greene & MacRae, L.L.P. advised Hillenbrand on the transaction. KBW issued a fairness opinion related to the transaction. The consummation of the transaction is subject to various conditions, including, financing, and regulatory and government approvals. The approvals include those of certain state insurance commissioners and the Office of Thrift Supervision. The transaction is anticipated to close in Hillenbrand s fiscal 2004 third quarter. Forethought was organized by Hillenbrand Industries in 1985 to meet a growing customer demand for tax-advantaged, portable and competitive funeral planning products. Forethought serves funeral-planning professionals with marketing support for pre-arranged funeral services funded by life insurance policies and trust products. Its life insurance policies are offered by approximately 5,000 independent funeral home locations. In addition, Forethought manages an investment portfolio in excess of $3.3 billion that focuses on opportunities to enhance yield and improve credit quality while minimizing future risk. Forethought consists of the following subsidiaries: Forethought Life Insurance Company; Forethought Federal Savings Bank; Forethought Life Assurance Company; Arkansas National Life Assurance Company; and The Forethought Group, Inc. 2

HILLENBRAND INDUSTRIES, INC. Hillenbrand Industries, Inc., headquartered in Batesville, Indiana, is a publicly traded holding company for three major wholly owned businesses serving the health care and funeral services industries. All three subsidiaries have headquarters in Batesville. Hill-Rom Company is a recognized manufacturer of equipment for the healthcare industry and a provider of associated services for wound, pulmonary and circulatory care, as well as providing medical equipment outsourcing and asset management services. Batesville Casket Company and Forethought both serve the funeral services industry. Batesville Casket is a leading manufacturer and supplier of burial caskets, cremation products and related services to licensed funeral homes, while Forethought is a leading provider of insurance and trust-based financial products and services for preplanning funeral services. DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS: Certain statements in this press release contain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, regarding Hillenbrand s future plans, objectives, beliefs, expectations, representations and projections. Hillenbrand has tried, wherever possible, to identify these forward-looking statements using words such as approximately, focusing, enhance, anticipated, estimated, future, should, expects, expected, and will, but their absence does not mean that the statement is not forward-looking. Forwardlooking statements include, without limitation, statements regarding what is in the best interests of shareholders, the consummation of Forethought s sale, the transaction s structure and proceeds, achievements of Forethought s full business potential, and the effects of the sale of Forethought on the Company s future results of operations. It is important to note that actual results could differ materially from those in any such forward-looking statements. They are not guarantees of future performance. Factors that could cause actual results to differ are included in the Company s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission. Readers should also refer to the various disclosures made by Hillenbrand in its periodic reports on Forms 10-K, 10-Q and 8-K filed with the U.S. Securities and Exchange Commission. CONTACTS: Hillenbrand Industries: Wendy Wilson, Vice President, Investor Relations, 812-934-7670, Christopher P. Feeney, Director Corporate Communications, 812-934-8197 ### 3 End of Filing 2005 EDGAR Online, Inc.